Sector News

Ferring buys BioSET’s orthobiologics

February 19, 2015
Life sciences
Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair.
 
The candidates in question, Amplex and Prefix, are based on “a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair”, Ferring says. They will be investigated for fusion in foot/ankle and lumbar spine surgical procedures, respectively.
 
Orthopaedics has become a key area for Ferring since the 2005 launch of Euflexxa (1% sodium hyaluronate) for knee pain and buying the BioSET portfolio builds on that. Chief operating officer Michel Pettigrew said that “by developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery”.
 
No financial terms have been disclosed. Switzerland-headquartered Ferring noted that each year some two million procedures involving bone graft materials, including 700,000 fusions, are performed in the USA alone.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.